9062Background: MET amplification (amp) has been reported in a subset of NSCLC with the frequency varying depending on the definition used. Crizotinib, an ALK/ROS1/MET inhibitor approved in ALK- or ROS1-positive NSCLC, also has proven clinical activity in cases of MET exon 14 alterations and MET amp. Here we present an updated analysis of crizotinib in pts with low, medium (med), and high (hi) levels of MET amp in advanced NSCLC. Methods: In this ongoing, open-label, multicenter, phase 1 trial (NCT00585195), MET amp was locally tested; pts with MET/CEP7 ratios ≥1.8 were eligible. Pts received crizotinib 250 mg BID and were assigned to categories based on low (≥1.8–≤2.2), med ( > 2.2– 2.2– < 4 and ≥4; data were then reanalyzed to better delineate predictive biomarkers of response. Selected endpoints included best overall response (BOR) per RECIST v1.0, time to tumor response (TTR), progression-free survival (PFS), duration of respo...